Skip to content

The impact of whole body heating on blood flow distribution and temperature regulation in chronic heart failure patients

The effect of repeated whole body heating on blood flow distribution to skin, muscle and cerebral vessel beds and thermoregulatory responses in chronic heart failure patients.

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000361707
Enrollment
100
Registered
2013-04-05
Start date
2018-10-31
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Patients with chronic heart failure (CHF) have an impaired capacity to regulate body temperature. This study will investigate the acute effects of body heating in patients with CHF and also the effects of repetitive exposure to whole body heating. Participants will be recruited from general Cardiology at RPH, from private Cardiology clinics and from the Cardiac Transplant Unit and Advanced Heart Failure Service at RPH. Study hypotheses: 1. Patients with CHF will exhibit impaired cardiovascular responses to an acute bout of body heating, compared to age, gender and BMI matched controls. 2. Repeated whole body heating will improve abnormal cardiovascular function evident in response to body heating in patients with CHF.

Interventions

Responses to warm water immersion (maintained at a constant temperature of approximately 36 degrees celcius), to the waist level for a period of 30 minutes. During this period, skeletal muscle, cerebral and skin blood flows will be measured as well as sweat rate production and core temperature changes. Subsequently, the warm water heating protocol will be repeated 3 times per week for a period of 10 weeks. CHF subjects will be randomised to either the warm water heating in a bath for 30 minute

Responses to warm water immersion (maintained at a constant temperature of approximately 36 degrees celcius), to the waist level for a period of 30 minutes. During this period, skeletal muscle, cerebral and skin blood flows will be measured as well as sweat rate production and core temperature changes. Subsequently, the warm water heating protocol will be repeated 3 times per week for a period of 10 weeks. CHF subjects will be randomised to either the warm water heating in a bath for 30 minutes 3 times a week or to a euthermic bath control group. Warm water immersion will be conducted in custom-made water bath, whereby participants will sit immersed in water to the waist level. This method of heating the body has been chosen because it allows the study to be performed in a supervised environment. It also allows us to measure the effect of heating on the whole body, including body parts not immersed in the heating stimulus (i.e. the arms, which will be kept out of the water). The bath temperature will be similar to that which would be experienced in a warm bath or spa at home (ie 32-38 degrees C). The water temperature is thermostatically controlled using specialised equipment (iCool, Queensland). Blood pressure and heart rate will be continuously monitored during these sessions to provide information regarding each subject's tolerance of the warm bath. If this becomes uncomfortable at any stage, the water temperature will be cooled or the participant will be allowed to leave the bath. The group allocated to the euthermic water exposure will be positioned in an identical custom-made bath for 30 minutes and will be monitored in an identical fashion to those allocated to warm water immersion, however, the temperature of the water in the euthermic group will be thermostatically controlled to room temperature using specialised equipment (iCool, Queensland).

Sponsors

Royal Perth Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with New York Heart Association Class I-III CHF (aetiology either ischaemic or idiopathic dilated cardiomyopathy) A group of subjects who do not have CHF will be recruited as controls. These control subjects will be matched for age, sex and body composition.

Exclusion criteria

Recent history of syncope (past 6 months) Systolic blood pressure < 90mmHg New York Heart Association Class IV Recent exacerbation of heart failure resulting in hospitalisation (< 2months)

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026